Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 15/20 | 1.00 |
| ▸ | CCNC | P24863 | 14/20 | 1.00 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.77 |
| ▸ | SELE | P16581 | 9/20 | 0.77 |
| ▸ | VCAM1 | P19320 | 6/20 | 0.77 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.74 |
| ▸ | CDK9 | P50750 | 1/20 | 0.74 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.60 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.60 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7054426 | 0.89 | CCNC (0.80) | CDK8CCNCICAM1SELEVCAM1 | |
| SCHEMBL7051842 | 0.89 | CDK8 (1.00) | CDK8CCNCICAM1SELEVCAM1 | |
| SCHEMBL7054707 | 0.88 | CCNC (0.79) | CDK8CCNCICAM1SELEVCAM1 | |
| SCHEMBL5555774 | 0.88 | MAP3K8 (0.80) | CDK8CCNCICAM1SELEVCAM1 | |
| SCHEMBL7856364 | 0.88 | CDK8 (1.00) | CDK8CCNCICAM1SELEVCAM1 | |
| SCHEMBL7053786 | 0.87 | CCNC (0.77) | CDK8CCNCICAM1SELEVCAM1 | |
| SCHEMBL7055341 | 0.87 | ICAM1 (1.00) | CDK8CCNCICAM1SELEVCAM1 | |
| SCHEMBL7050900 | 0.87 | CCNC (0.83) | CDK8CCNCICAM1SELEVCAM1 | |
| SCHEMBL7058294 | 0.86 | ICAM1 (0.78) | CDK8CCNCICAM1SELEVCAM1 | |
| SCHEMBL7055169 | 0.85 | ICAM1 (1.00) | CDK8CCNCICAM1SELEVCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | claimed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | claimed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | claimed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | claimed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | claimed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | claimed |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6579882-B2 | Thieno(2,3-d)pyrimidine derivatives | ABBOTT LABORATORIES | 2003-06-17 | — | — | US | disclosed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | disclosed |
| US-6232320-B1 | THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES | ABBOTT LABORATORIES | 2001-05-15 | — | — | US | disclosed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | CDK8 2986/4885CCNC 1780/4885ICAM1 1/4885 |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | CDK8 2986/4885CCNC 1780/4885ICAM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.